Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin initial dose adjustment using GRAIL versus Cockcroft-Gault in liver transplant recipients
IRCT20100111003043N14Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of vancomycin in bacterial disease (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Initial vancomycin dose design, Vancomycin trough blood concentration and 4 more. Started Nov 2019; status: completed.
02
Drugs
vancomycin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on IRCT20100111003043N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100111003043N14.